Rocket Pharma Shares Plunge 15% as Commercialization Doubts Overshadow FDA Approval
RCKT sits 76% above its 52-week low of $2.19 on elevated volume (5.5× avg).
Summary
Rocket Pharmaceuticals' shares plunged over 15% today, despite the company receiving accelerated FDA approval for Kresladi, its gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). This negative market reaction follows earlier news and an 8-K filing today announcing the FDA approval, which initially saw the stock rise. Investors are now focusing on significant commercialization hurdles, including the company's plan for a limited phased launch, commercial availability not expected until Q4 2026, and the lack of disclosed pricing. Analysts suggest these practical challenges and the company's decision not to actively market Kresladi are limiting patient uptake expectations, overshadowing the clinical achievement. Future updates on reimbursement, pricing strategy, and the actual launch trajectory will be critical catalysts.
At the time of this announcement, RCKT was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $417.6M. The 52-week trading range was $2.19 to $8.26. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.